Head-to-head clinical analysis & difference comparison: details on mechanism of action, dosing, half-life, interactions, and maternal-fetal safety.
FLAGYL vs FLAGYL ER
Clinician-reviewed, head-to-head comparison of mechanism, dosing, pharmacokinetics, and safety profiles.
Last clinically reviewed: July 2026 · OpiCalc Medical Review Team
Metronidazole, a nitroimidazole antibiotic, enters bacterial cells and is reduced to cytotoxic intermediates that damage DNA and inhibit nucleic acid synthesis, leading to cell death. It is active against anaerobic bacteria and protozoa.
Metronidazole, a nitroimidazole antibiotic, undergoes intracellular reduction by bacterial nitroreductases, forming cytotoxic compounds that damage DNA and inhibit nucleic acid synthesis, selectively targeting anaerobic bacteria and protozoa.
Bacterial vaginosis,Trichomoniasis,Amebiasis,Giardiasis,Anaerobic bacterial infections (intra-abdominal, gynecologic, skin and soft tissue, bone and joint, central nervous system, lower respiratory tract, endocarditis, septicemia),Helicobacter pylori eradication (in combination with other agents),Crohn's disease (off-label),Rosacea (topical, off-label oral use is controversial),Prevention of postoperative infection following colorectal surgery
Treatment of bacterial vaginosis (FDA-approved),Off-label: Clostridium difficile infection, anaerobic infections, trichomoniasis, amebiasis, giardiasis, rosacea, periodontal disease, Helicobacter pylori eradication
Metronidazole 500 mg intravenously every 8 hours or 500 mg orally every 8 hours.
750 mg orally once daily for 10 days for bacterial vaginosis.
Terminal elimination half-life: 6-8 hours in adults with normal renal function; prolonged to 7-21 hours in hepatic impairment; no significant change in renal impairment; clinically relevant for dosing interval (usually 8-hourly).
Terminal elimination half-life: 6-8 hours (increased to 10-12 hours with hepatic impairment; unchanged in renal impairment).
Hepatic metabolism via oxidation and glucuronidation; major metabolites include hydroxy metabolite (active) and acid metabolite. CYP450 enzymes involved (CYP2A6, CYP2C9, CYP3A4).
Hepatic metabolism via side-chain oxidation and glucuronidation; metabolites are 5-nitroimidazoles and hydroxy metabolites; CYP450 enzymes (CYP2A6, CYP3A4, CYP2B6) partially involved.
Renal: 60-80% of dose excreted unchanged in urine; biliary/fecal: 6-15% as metabolites and unchanged drug; enterohepatic circulation contributes to prolonged elimination.
Renal: 60-80% (metabolites and unchanged drug). Fecal: 6-15%. Minimal biliary.
Less than 20% bound to plasma proteins (primarily albumin).
<20% (albumin).
Volume of distribution: 0.6-0.8 L/kg (approximately 40-60 L in adults), indicating extensive tissue penetration; exceeds total body water, consistent with distribution into all tissues including abscess cavities and CNS.
0.5-0.8 L/kg; indicates extensive tissue distribution including CNS.
Oral bioavailability: 80-100% (well absorbed); IV bioavailability: 100% (by definition); Topical: Systemic absorption minimal (<2%).
Oral: 80-95% (extended-release formulation).
No dose adjustment required for mild to moderate renal impairment (GFR >10 m L/min). For severe renal impairment (GFR <10 m L/min), reduce dose to 500 mg every 12 hours.
No adjustment necessary for GFR >10 m L/min; for GFR <10 m L/min, consider using immediate-release metronidazole instead of FLAGYL ER due to lack of data in severe renal impairment.
Child-Pugh A: no adjustment. Child-Pugh B: reduce dose by 50% (e.g., 250 mg every 8 hours). Child-Pugh C: reduce dose to 250 mg every 12 hours.
Child-Pugh Class A/B: no adjustment necessary. Child-Pugh Class C: reduce dose to 375 mg orally once daily (50% of usual dose).
15-50 mg/kg/day intravenously or orally divided every 8 hours, depending on infection type and severity. Maximum 4 g/day.
Safety and efficacy not established for FLAGYL ER in pediatric patients. Use immediate-release metronidazole for pediatric dosing.
Monitor renal function; same dosing as adults unless severe renal impairment (Cr Cl <10 m L/min) requires dose reduction to 500 mg every 12 hours.
No specific dose adjustment recommended based on age alone; use caution due to potential for decreased renal function and monitor for adverse effects.
Carcinogenicity: Metronidazole has been shown to be carcinogenic in mice and rats. Chromosomal aberrations have been reported in patients with Crohn's disease and other conditions. Use should be reserved for approved indications only.
Carcinogenicity: Metronidazole has been shown to be carcinogenic in mice and rats. Avoid chronic use. Reserved for anaerobic and protozoal infections.
Carcinogenicity risk (see black box warning),Neurologic effects: peripheral neuropathy, seizures, encephalopathy; discontinue if abnormal neurologic signs occur,Hematologic effects: leukopenia, neutropenia; monitor CBC,Hepatic impairment: dosage adjustment recommended,Metronidazole may cause metallic taste, dark urine, and disulfiram-like reaction with alcohol,Prolonged use may result in superinfection (e.g., C. difficile diarrhea),Potential for ethylene glycol toxicity if administered with propylene glycol-containing solutions
Peripheral neuropathy (risk with prolonged use), CNS effects (seizures, encephalopathy), disulfiram-like reaction with alcohol, sodium overload (each tablet contains 84 mg sodium), hepatic impairment may increase risk of toxicity, renal impairment (dose adjustment not typically required but monitor), superinfection including C. difficile diarrhea.
Hypersensitivity to metronidazole or other nitroimidazole derivatives,First trimester of pregnancy (avoid; use during later trimesters only if clearly needed),Breastfeeding (discontinue drug or bottle-feed; excreted in breast milk),History of blood dyscrasias,Concurrent use of disulfiram (psychotic reactions may occur; wait at least 2 weeks after disulfiram),Concurrent use of propylene glycol-containing IV formulations in neonates or patients with renal impairment
Hypersensitivity to metronidazole or other nitroimidazoles; concurrent use of disulfiram (psychotic reactions); caution in pregnancy (first trimester only if clearly needed; crosses placenta); breastfeeding (use caution due to potential carcinogenicity).
Avoid alcohol and any products containing ethanol (including certain mouthwashes, cough syrups, and fermented foods) during therapy and for at least 48 hours after last dose. No other food restrictions.
Avoid alcohol and any products containing alcohol (e.g., mouthwash, cough syrups, cooking wine) during therapy and for 48 hours after last dose. No specific food restrictions otherwise.
Flagyl (metronidazole) crosses the placenta. In the first trimester, use is generally avoided due to theoretical risk of teratogenicity, but data from large cohort studies do not show a significant increase in major malformations (risk category B). In the second and third trimesters, no fetal harm has been demonstrated; however, use only if clearly needed. High doses associated with fetal toxicity in animals.
Trimester 1: Crosses placenta; contraindicated in first trimester due to risk of carcinogenicity in animal studies and potential teratogenicity; use only for life-threatening infections. Trimester 2 and 3: Use with caution; associated with increased risk of cleft lip/palate in some studies; avoid if possible.
Metronidazole is excreted into breast milk with an M/P ratio of approximately 0.9-1.5. After a single 2 g oral dose, peak milk concentration ~10-20 mcg/m L. The American Academy of Pediatrics considers it compatible with breastfeeding, but because of potential mutagenicity, avoid high doses (e.g., 2 g single dose) for 12-24 hours; resume breastfeeding after 2-3 half-lives. Lower doses (250-500 mg) are considered safe.
Excreted in breast milk; M/P ratio ~0.9; American Academy of Pediatrics considers compatible with breastfeeding, but advise caution; monitor infant for diarrhea or oral thrush.
No specific dose adjustment for pregnancy. However, due to increased plasma volume and renal clearance, standard doses (e.g., 500 mg IV every 6-8 hours) may require monitoring for efficacy. Oral bioavailability unchanged. Use with caution if hepatic impairment.
No specific dose adjustments recommended based on pregnancy pharmacokinetics; however, due to increased GFR in pregnancy, consider monitoring therapeutic levels for severe infections.
Flagyl (metronidazole) is first-line for anaerobic infections and bacterial vaginosis. It can cause a disulfiram-like reaction with alcohol; avoid ethanol during therapy and for 48 hours after last dose. Monitor for peripheral neuropathy with prolonged use. IV formulation is highly irritating; avoid extravasation. Use with caution in hepatic impairment; dose reduction may be needed. Metallic taste is common but benign.
FLAGYL ER (metronidazole extended-release) is indicated for bacterial vaginosis. Avoid alcohol during therapy and for 48 hours after completion due to disulfiram-like reaction. Monitor for peripheral neuropathy; discontinue if signs occur. Use with caution in hepatic impairment; dose adjustment may be needed. May cause metallic taste.
Do not drink alcohol or use products containing alcohol during treatment and for 48 hours after the last dose to avoid severe nausea, vomiting, and flushing.,Take with food to reduce gastrointestinal upset.,Complete the full course even if symptoms improve to prevent resistance.,May cause a metallic taste, which is temporary.,Avoid sexual intercourse or use condoms during treatment for trichomoniasis; partners may need treatment.,Notify doctor if you experience numbness, tingling, or pain in hands/feet.,For vaginal gel, avoid alcohol-containing products (e.g., douches) for 24 hours after use.
Take this medication exactly as prescribed; do not crush or chew the extended-release tablets.,Avoid all alcohol and alcohol-containing products during treatment and for 48 hours after the last dose to prevent severe nausea, vomiting, and flushing.,Complete the full course even if symptoms improve to ensure infection is fully treated.,Report any numbness, tingling, or pain in hands or feet to your doctor immediately.,Inform your healthcare provider if you have liver disease, a history of blood disorders, or are pregnant or breastfeeding.
No interactions on record
No interactions on record
Explore head-to-head clinical comparisons of other medications in the same therapeutic classes.
Common clinical questions about FLAGYL vs FLAGYL ER, answered by our medical review team.
FLAGYL is a Nitroimidazole Antibiotic that works by Metronidazole, a nitroimidazole antibiotic, enters bacterial cells and is reduced to cytotoxic intermediates that damage DNA and inhibit nucleic acid synthesis, leading to cell death. It is active against anaerobic bacteria and protozoa.. FLAGYL ER is a Nitroimidazole Antibiotic that works by Metronidazole, a nitroimidazole antibiotic, undergoes intracellular reduction by bacterial nitroreductases, forming cytotoxic compounds that damage DNA and inhibit nucleic acid synthesis, selectively targeting anaerobic bacteria and protozoa.. They differ in pharmacokinetic profiles, FDA-approved indications, and side effect profiles.
Potency comparisons between FLAGYL and FLAGYL ER depend on the specific clinical indication. These are both Nitroimidazole Antibiotic agents and are not directly interchangeable by dose. A physician or clinical pharmacist should guide any therapeutic switching decisions.
The standard adult dose of FLAGYL is: Metronidazole 500 mg intravenously every 8 hours or 500 mg orally every 8 hours.. The standard adult dose of FLAGYL ER is: 750 mg orally once daily for 10 days for bacterial vaginosis.. Dosing should always be individualized based on indication, renal and hepatic function, age, and other patient factors.
No direct drug-drug interaction has been formally documented between FLAGYL and FLAGYL ER in current clinical databases. However, individual patient risk factors including other medications, organ function, and comorbidities should always be evaluated by a qualified healthcare provider.
The maternal-fetal safety profiles differ. FLAGYL is classified as Category C. Flagyl (metronidazole) crosses the placenta. In the first trimester, use is generally avoided due to theoretical risk of teratogenicity, but data from large cohort studies do not s. FLAGYL ER is classified as Category C. Trimester 1: Crosses placenta; contraindicated in first trimester due to risk of carcinogenicity in animal studies and potential teratogenicity; use only for life-threatening infec. Always consult a maternal-fetal medicine specialist before taking either drug during pregnancy or lactation.